A Study Of Efficacy And Safety With Apatinib Or Apatinib Combined With Chemotherapy In Recurrent/advanced Ovarian Cancer Patients

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Grossman DC, Curry SJ, Owens DK, et al. Screening for ovarian cancer: US preventive services task force recommendation statement. JAMA. 2018;319(6):588–594. doi:10.1001/jama.2017.2192629450531
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132. doi:10.3322/caac.2133826808342
   PubMed Web of Science ®Google Scholar
• Korkmaz T, Seber S, Basaran G. Review of the current role of targeted therapies as maintenance therapies in first and second line treatment of epithelial ovarian cancer; in the light of completed trials. Crit Rev Oncol Hematol. 2016;98:180–188. doi:10.1016/j.critrevonc.2015.10.00626603345
   PubMed Web of Science ®Google Scholar
• Li J, Qin S, Xu J, et al. Randomized, double-blind, placebo-controlled Phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J Clin Oncol. 2016;34(13):1448–1454. doi:10.1200/JCO.2015.63.599526884585
   PubMed Web of Science ®Google Scholar
• Gong XL, Qin SK. Progress in systemic therapy of advanced hepatocellular carcinoma. World J Gastroenterol. 2016;22(29):6582–6594. doi:10.3748/wjg.v22.i29.658227547002
   PubMed Web of Science ®Google Scholar
• Qin SK. Apatinib in Chinese patients with advanced hepatocellular carcinoma: a phaseⅡ randomized, open-label trial. J Clin Oncol. 2014;32 Suppl 5:abstract4019. doi:10.1200/jco.2014.32.15_suppl.4019
   Web of Science ®Google Scholar
• Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32:1302–1308. doi:10.1200/JCO.2013.51.448924637997
   PubMed Web of Science ®Google Scholar
• Du Bois A, Floquet A, Kim JW, et al. Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol. 2014;32:3374–3382. doi:10.1200/JCO.2014.55.734825225436
   PubMed Web of Science ®Google Scholar
• Laganà AS, Sofo V, Vitale SG, Triolo O. Epithelial ovarian cancer inherent resistance: may the pleiotropic interaction between reduced immunosurveillance and drug-resistant cells play a key role. Gynecol Oncol Rep. 2016;18:57–58. doi:10.1016/j.gore.2016.09.00427995176
   PubMed Web of Science ®Google Scholar
• Laganà AS, Colonese F, Colonese E, et al. Cytogenetic analysis of epithelial ovarian cancer’s stem cells: an overview on new diagnostic and therapeutic perspectives. Eur J Gynaecol Oncol. 2015;36(5):495–505.26513872
   PubMed Web of Science ®Google Scholar
• Hamerlik P, Lathia JD, Rasmussen R, et al. Autocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth. J Exp Med. 2012;209(3):507–520. doi:10.1084/jem.2011142422393126
   PubMed Web of Science ®Google Scholar
• Burger RA, Brady MF, Rhee J, et al. Independent radiologic review of the Gynecologic Oncology Group Study 0218, a phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer. Gynecol Oncol. 2013;131(1):21–26. doi:10.1016/j.ygyno.2013.07.10023906656
   PubMed Web of Science ®Google Scholar
• Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473–2483. doi:10.1056/NEJMoa110439022204724
   PubMed Web of Science ®Google Scholar
• Coleman RL, Brady MF, Herzog TJ, et al. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18(6):779–791. doi:10.1016/S1470-2045(17)30279-628438473
   PubMed Web of Science ®Google Scholar
• Pujade-Lauraine E, Ledermann JA, Selle F, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(9):1274–1284. doi:10.1016/S1470-2045(17)30469-228754483
   PubMed Web of Science ®Google Scholar
• Coleman RL, Oza AM, Lorusso D, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10106):1949–1961. doi:10.1016/S0140-6736(17)32440-628916367
   PubMed Web of Science ®Google Scholar
• Moore KN, Vergote I, Oaknin A, et al. FORWARD I: a Phase III study of mirvetuximabsoravtansine versus chemotherapy in platinum-resistant ovarian cancer. Future Oncol. 2018;14(17):1669–1678. doi:10.2217/fon-2017-064629424243
   PubMed Web of Science ®Google Scholar
• Moore KN, O’Malley DM, Vergote I, et al. Safety and activity findings from a phase 1b escalation study of mirvetuximabsoravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer. Gynecol Oncol. 2018;151(1):46–52. doi:10.1016/j.ygyno.2018.07.01730093227
   PubMed Web of Science ®Google Scholar
• Moore KN, Martin LP, O’Malley DM, et al. Safety and activity of mirvetuximabsoravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Phase I expansion study. J Clin Oncol. 2017;35(10):1112–1118. doi:10.1200/JCO.2016.69.953828029313
   PubMed Web of Science ®Google Scholar
• Zhang H. Apatinib for molecular targeted therapy in tumor. Drug Des Devel Ther. 2015;9:6075–6081.
   PubMed Web of Science ®Google Scholar
• Qin SK, Li J. Clinical expert consensus of gastric carcinoma treated with apatinib. Chin Clinl Oncol. 2015;9:841–847.
   Google Scholar
• National Comprehensive Cancer Network, Inc. NCCN clinical practice guidelines in oncology: gastric cancer (Version2.2015). 2015 Available from: http://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf. Accessed 926, 2019.
   Google Scholar
• Lan CY, Wang Y, Xiong Y, et al. Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study. Lancet Oncol. 2018;19(9):1239–1246. doi:10.1016/S1470-2045(18)30349-830082170
   PubMed Web of Science ®Google Scholar
• Vitale SG, Capriglione S, Zito G, et al. Management of endometrial, ovarian and cervical cancer in the elderly: current approach to a challenging condition. Arch Gynecol Obstet. 2019;299(2):299–315. doi:10.1007/s00404-018-5006-z30542793
   PubMed Web of Science ®Google Scholar
• Schuurman MS, Kruitwagen R, Portielje J, et al. Treatment and outcome of elderly patients with advanced stage ovarian cancer: a nationwide analysis. Gynecol Oncol. 2018;149(2):270–274. doi:10.1016/j.ygyno.2018.02.01729514738
   PubMed Web of Science ®Google Scholar
• Bellia A, Vitale SG, Laganà AS, et al. Feasibility and surgical outcomes of conventional and robot-assisted laparoscopy for early-stage ovarian cancer: a retrospective, multicenter analysis. Arch Gynecol Obstet. 2016;294(3):615–622. doi:10.1007/s00404-016-4087-927040423
   PubMed Web of Science ®Google Scholar
• Sun D, Hou H, Zhang C, Zhang X. The efficacy and safety of apatinib for refractory malignancies: a review and meta-analysis. Onco Targets Ther. 2018;11:6539–6554. doi:10.2147/OTT.S17642930323627
   PubMed Web of Science ®Google Scholar